Publication | Closed Access

Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-α after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen

Sequential AdministrationMedicineMelanomaImmunologyImmune Checkpoint InhibitorPharmacotherapyImmunotherapeuticsAdvanced Malignant MelanomaDermatologyIntravenous DacarbazineImmunotherapyOncology